The debate revealed fundamental disagreement about whether C1q has spatially distinct functions at synapses versus microglia, or whether outcomes depend solely on binding partners. This mechanistic uncertainty undermines all proposed therapeutic strategies targeting C1q.
Source: Debate session sess_SDA-2026-04-12-gap-debate-20260410-112848-7ba6c2e1 (Analysis: SDA-2026-04-12-gap-debate-20260410-112848-7ba6c2e1)
Under this model, C1q is a context decoder whose downstream program depends chiefly on the biochemical identity of the complex it forms, such as neuronal pentraxins, Aβ aggregates, apoptotic membranes, or ECM ligands. Spatial localization remains relevant, but as a secondary variable relative to ligand chemistry and complex composition.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Target Gene: C1QAC1QBC1QCNPTX1NPTX2APPC3"]
B["Molecular Mechanism Pathway Activation"]
C["Cellular Phenotype Neuronal / Glial Response"]
D["Network Effect Circuit-Level Consequence"]
E["Disease Relevance Neurodegeneration Link"]
A --> B --> C --> D --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#1b5e20,stroke:#81c784,color:#81c784
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations5 with PMIDValidation: 0%3 supporting / 2 opposing
✓For(3)
No supporting evidence
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
5
MECH 5CLIN 0GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
C1q binds diverse ligands including Aβ, indicating…
No decisive CNS study yet demonstrates that ligand identity explains more variance than location when ligand, …▼
No decisive CNS study yet demonstrates that ligand identity explains more variance than location when ligand, receiver cell, and complement competence are independently controlled.
Microenvironmental geometry, local complement regulators, and which cell encounters the complex first may riva…▼
Microenvironmental geometry, local complement regulators, and which cell encounters the complex first may rival or exceed ligand identity in determining outcome.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-25 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Synaptic C1q drives complement-dependent pruning, while microglial surface-associated C1q biases phagocyte state through receptor-specific signaling
Mechanism: C1q deposited on weak or stressed synapses preferentially nucleates the classical complement cascade (`C1q -> C4 -> C3`), generating opsonins that engage microglial CR3/ITGAM-ITGB2 and promote engulfment. In contrast, C1q bound directly to microglial receptors or pericellular ligands may alter microglial transcriptional state without requiring full downstream complement activation. This would make localization mechanis
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Overall skeptical read: the debate is probably mixing three separable variables that have not been cleanly orthogonalized experimentally: `location`, `ligand identity`, and `receiver-cell state`. The strongest evidence supports synaptic C1q/C3/CR3-mediated pruning in development and AD models, but that does not by itself prove a distinct microglial surface-signaling program for C1q, nor a binding-partner hierarchy that dominates location. Much of the translational logic is still mouse-heavy and disease-model dependent. Key anchors: synaptic pruning by C1q/C3 in development ([PMID: 18083105](ht
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Triage
The ideas worth carrying forward are `6`, `5`, `1`, `2`, `4`, and `7`, in that order. I would drop `3` for now; it is too speculative to support a drug program.
The main translational point is that only one of these is close to a druggable thesis today: `block classical-pathway activation downstream of C1q` rather than trying to solve all C1q biology first. The rest are mostly mechanism, stratification, or endpoint-selection hypotheses.
Feasibility: Highest. This is the cleanest therapeutic hypothesis becaus
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses":[{"title":"Selective blockade of classical-pathway activation downstream of C1q will reduce synaptotoxic complement amplification while preserving beneficial C1q recognition functions","description":"The most actionable synthesis is that pathogenicity may depend more on conversion of C1q binding into classical-pathway protease activity than on C1q recognition alone. In this model, inhibiting C1r/C1s should attenuate C4/C3-mediated synapse loss and neuroinflammation while preserving some homeostatic debris sensing and cargo recognition by C1q.","target_gene":"C1QA,C1QB,C1QC